Qiliqiangxin capsule improves cardiac remodeling in rats with DOCA-salt-induced diastolic dysfunction.

Aug 22, 2023European review for medical and pharmacological sciences

Qiliqiangxin capsule improves heart structure in rats with high blood pressure-related heart relaxation problems

AI simplified

Abstract

Qiliqiangxin treatment significantly improved heart function in a rat model of heart failure with preserved ejection fraction (HFpEF).

  • QL treatment led to a decrease in cardiac index and an increase in ejection fraction and E/A ratio compared to the Model group.
  • QL reduced left ventricular wall thickness and improved isovolumic diastolic time and contraction time metrics.
  • Treatment with QL significantly lowered serum levels of NT-ProBNP, a marker of heart failure.
  • QL inhibited fibrosis deposition and myocardial hypertrophy, as evidenced by Masson and WGA staining.
  • QL reduced protein levels associated with cardiac remodeling, including TGF-β1, MMP2, and MMP9.
  • QL treatment decreased pro-inflammatory cytokines TNF-α and IL-2, while increasing IL-10 concentration.

AI simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free